Urogen Pharma (NASDAQ:URGN) Stock Price Expected to Rise, HC Wainwright Analyst Says

Urogen Pharma (NASDAQ:URGN) had its price target raised by equities researchers at HC Wainwright from $45.00 to $75.00 in a research report issued on Thursday, MarketBeat reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 59.71% from the company’s current price. HC Wainwright also issued estimates for Urogen Pharma’s Q3 2027 earnings at $0.36 EPS and Q4 2027 earnings at $0.50 EPS.

Other equities analysts also recently issued research reports about the stock. UBS Group reissued a “buy” rating on shares of Urogen Pharma in a report on Thursday, July 9th. Guggenheim lifted their price target on shares of Urogen Pharma from $32.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, July 21st. Jefferies Financial Group raised Urogen Pharma to a “strong-buy” rating in a report on Friday, April 24th. The Goldman Sachs Group reiterated a “neutral” rating and set a $44.00 target price on shares of Urogen Pharma in a research report on Wednesday, July 15th. Finally, TD Cowen boosted their price target on Urogen Pharma from $50.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $48.78.

Urogen Pharma Stock Up 3.0%

Urogen Pharma stock opened at $46.96 on Thursday. Urogen Pharma has a twelve month low of $15.86 and a twelve month high of $48.19. The company has a market capitalization of $2.30 billion, a P/E ratio of -23.72 and a beta of 1.57. The stock’s 50 day moving average is $36.44 and its 200 day moving average is $27.12.

Urogen Pharma (NASDAQ:URGN) last released its earnings results on Wednesday, August 5th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The firm had revenue of $72.46 million during the quarter, compared to analysts’ expectations of $63.55 million. As a group, equities analysts expect that Urogen Pharma will post -0.76 EPS for the current year.

Insider Transactions at Urogen Pharma

In other Urogen Pharma news, insider Mark Schoenberg sold 10,000 shares of the firm’s stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $40.00, for a total transaction of $400,000.00. Following the sale, the insider directly owned 119,763 shares of the company’s stock, valued at $4,790,520. This trade represents a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 25,222 shares of company stock valued at $892,661. Corporate insiders own 4.80% of the company’s stock.

Institutional Investors Weigh In On Urogen Pharma

A number of institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new position in shares of Urogen Pharma in the second quarter worth $117,814,000. Deutsche Bank AG purchased a new position in shares of Urogen Pharma during the second quarter valued at about $1,897,000. Rice Hall James & Associates LLC bought a new stake in shares of Urogen Pharma in the second quarter worth about $11,064,000. Persistent Asset Partners Ltd bought a new stake in shares of Urogen Pharma in the second quarter worth about $66,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Urogen Pharma in the second quarter worth about $4,159,000. 91.29% of the stock is owned by hedge funds and other institutional investors.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.